Incretin & metabolic research compounds
5-Amino-1MQ
Also known as 5A1MQ · 5-amino-1-methylquinolinium
A small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT), studied in obesity and metabolism models.
In 60 seconds
Preclinical: diet-induced-obese mouse studies (alone and with diet change). No human safety data.
- In diet-induced obese mice, the NNMT inhibitor 5A1MQ was studied for body composition, liver pathology and pharmacokinetics.
- In obese mice, 5-amino-1-methylquinolinium plus a low-fat diet rapidly normalised adiposity and altered the gut microbiome.
- Reviews how NNMT links metabolite levels to chromatin-modifying enzymes and gene regulation.
Mechanism
NNMT methylates nicotinamide using SAM, linking cellular energy (NAD+) balance and methylation capacity. It is over-expressed in adipose tissue in obesity; inhibiting it is proposed to raise NAD+ and shift fat-cell metabolism.
Research status
Preclinical: diet-induced-obese mouse studies (alone and with diet change). No human trials published.
Key studies
In diet-induced obese mice, the NNMT inhibitor 5A1MQ was studied for body composition, liver pathology and pharmacokinetics.
Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction — Diabetes Obes Metab, 2024 · PMID 39161060
In obese mice, 5-amino-1-methylquinolinium plus a low-fat diet rapidly normalised adiposity and altered the gut microbiome.
Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice — Sci Rep, 2022 · PMID 35013352
Reviews how NNMT links metabolite levels to chromatin-modifying enzymes and gene regulation.
Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation — Mol Metab, 2021 · PMID 33453420
A 2026 review of the prospects and obstacles for taking NNMT inhibitors into the clinic.
Emerging opportunities for nicotinamide N-methyltransferase (NNMT) inhibitor clinical translation — Trends Pharmacol Sci, 2026 · PMID 42067476
Safety signals in the literature
No human safety data. NNMT is also implicated in cancer biology, an active, separate research area.
Legal status (South Africa)
Approved incretin medicines are prescription-only (scheduled) in South Africa and available only through a prescriber; research-grade material is not a medicine and is not for human use.
Related compounds we stock
Not stocked yet — get notified
Tell us you want 5-Amino-1MQ and we’ll email you if we add it. Requests decide what we source next.
Not stocked yet
Get notified when we add 5-Amino-1MQ
One email, only when it reaches the catalogue. Every request is counted when we choose what to stock next.
Comparisons
Questions
What is 5-Amino-1MQ?
A small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT), studied in obesity and metabolism models. NNMT methylates nicotinamide using SAM, linking cellular energy (NAD+) balance and methylation capacity. It is over-expressed in adipose tissue in obesity; inhibiting it is proposed to raise NAD+ and shift fat-cell metabolism.
What is the research status of 5-Amino-1MQ?
Preclinical: diet-induced-obese mouse studies (alone and with diet change). No human trials published.
What safety signals are reported for 5-Amino-1MQ?
No human safety data. NNMT is also implicated in cancer biology, an active, separate research area.
Does Living Water Labs stock 5-Amino-1MQ?
Not at present. 5-Amino-1MQ is profiled here for reference, with citations to the published literature. You can ask to be notified if we add it. Approved incretin medicines are prescription-only (scheduled) in South Africa and available only through a prescriber; research-grade material is not a medicine and is not for human use.
More in Incretin & metabolic
Research reference only. This page summarises published literature; it is not medical advice and contains no guidance on human use. Products supplied by Living Water Labs are for laboratory research only.
